Evobrutinib

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H27N5O2
Molecular Weight	429.5142
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC=NC(NCC2CCN(CC2)C(=O)C=C)=C1C3=CC=C(OC4=CC=CC=C4)C=C3

InChI

InChIKey=QUIWHXQETADMGN-UHFFFAOYSA-N

InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)

HIDE SMILES / InChI

Molecular Formula	C25H27N5O2
Molecular Weight	429.5142
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30988116 | https://adisinsight.springer.com/drugs/800041955

Evobrutinib is a highly selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK). It potently inhibits BCR- and Fc receptor-mediated signaling and, thus, subsequent activation and function of B cells and innate immune cells such as monocytes and basophils. Evobrutinib demonstrated effectivity in autoimmune disease preclinical models. Evobrutinib is being developed by Merck Serono for the treatment of various autoimmune disorders.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tyrosine-protein kinase BTK 24 Target ID: Q06187 Gene ID: 695.0 Gene Symbol: BTK Target Organism: Homo sapiens (Human) Sources: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C141427 \| https://www.ncbi.nlm.nih.gov/pubmed/30988116	Inhibitor 8504		9.0 nM [IC50]

PubMed

Title	Date	PubMed
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.	2019-06-20	31075187
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.	2019-05-15	30988116

Sample Use Guides

In Vivo Use Guide

double-blind, randomized, phase 2 trial, we assigned patients with relapsing multiple sclerosis to one of five groups: placebo, evobrutinib (at a dose of 25 mg once daily, 75 mg once daily, or 75 mg twice daily), or open-label dimethyl fumarate (DMF) as a reference.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:26:12 GMT 2025` Edited by `admin` on `Wed Apr 02 09:26:12 GMT 2025`
Record UNII	ZA45457L1K
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Evobrutinib

Official Name

English

evobrutinib [INN]

Preferred Name

English

EVOBRUTINIB [USAN]

Common Name

English

2-Propen-1-one, 1-[4-[[[6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl]amino]methyl]-1-piperidinyl]-

Systematic Name

English

1-[4-[[[6-Amino-5-(4-phenoxyphenyl)-4-pyrimidinyl]amino]methyl]-1-piperidinyl]-2-propen-1-one

Systematic Name

English

MSC2364447C

Code

English

Evobrutinib [WHO-DD]

Common Name

English

M-2951

Code

English

MSC-2364447C

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C124801